NCT03149393 is a Phase 1, PHASE2 clinical trial of Qizhi Weitong Granules in Functional Dyspepsia, sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences.

Who is sponsoring NCT03149393?

NCT03149393 is sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences.

What drugs are being tested in NCT03149393?

Interventions in NCT03149393: Qizhi Weitong Granules, Mosapride Citrate Tablets.

What condition does NCT03149393 study?

NCT03149393 studies Functional Dyspepsia, Traditional Chinese Medicine.

Is NCT03149393 still recruiting?

NCT03149393 is currently status unknown. Last updated 28 February 2020.

Last reviewed 2020-02-28 · How we verify

NCT03149393

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study on Post Evaluation After Listing of Qizhi Weitong Granules

Status unknown Phase 1, PHASE2 Last updated 28 February 2020

What this trial tests

Phase 1, PHASE2 trial testing Qizhi Weitong Granules in Functional Dyspepsia in 384 participants. Status unknown.

Timeline

1 February 2017

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	384
Start date	1 February 2017
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

Qizhi Weitong Granules — full drug profile →
Mosapride Citrate Tablets — full drug profile →

Conditions studied

Functional Dyspepsia — all drugs for Functional Dyspepsia →
Traditional Chinese Medicine — all drugs for Traditional Chinese Medicine →

Sponsor

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Who can join

Adults 18 to 65, any sex, with Functional Dyspepsia or Traditional Chinese Medicine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a randomized, double blind, double dummy, multicenter, parallel controlled clinical trial, the investigators objective is to evaluate the efficacy and safety of Qizhi Weitong granules in the treatment of functional dyspepsia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical study on post evaluation after listing of Qizhi Weitong granules: Study protocol clinical trial (SPIRIT compliant).
Xu L, Zhang J, Li J, Lv L, et al · · 2020 · cited 2× · PMID 32311977 · DOI 10.1097/md.0000000000019758

Verify or expand the search:

Other recruiting trials for Functional Dyspepsia

Currently open trials in the same condition.

NCT07442734 — Auricular Stimulation for Functional Dyspepsia With Insomnia: Efficacy and Mechanisms · NA · recruiting
NCT07250308 — Correlation Study of Atrophic Gastritis and Dyspepsia Symptoms · recruiting
NCT07187492 — Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting
NCT07182890 — Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting
NCT07210294 — Press Needle on Body Acupuncture Points and Auricular Acupuncture Points on Functional Dyspepsia · NA · recruiting

Other Xiyuan Hospital of China Academy of Chinese Medical Sciences trials

Trials by the same sponsor.

NCT07518420 — Clinical Efficacy Evaluation of Chaizhi Hewei Decoction in the Treatment of Non-Erosive Reflux Disease With Liver-Stomac · NA · not yet recruiting
NCT06845254 — Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrom · Phase 3 · not yet recruiting
NCT06618495 — Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome · Phase 1, PHASE2 · completed
NCT06311890 — Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderat · Phase 2 · recruiting
NCT05638672 — COVID-19 Huashi Baidu Formula Clinical Study · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03149393 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiyuan Hospital of China Academy of Chinese Medical Sciences
Last refreshed: 28 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03149393.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing